Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

VERY HIGH-DOSE CYCLOPHOSPHAMIDE WITH IMIDAZOLE CARBOXIMIDE AND VINCRISTINE SULFATE IN THE TREATMENT OF STAGE-IV NEURO-BLASTOMA AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS Srinivasan, U., GLAUBIGER, D., Levine, A. S., Magrath, I. T., Pizzo, P. A., POPLACK, D. G. 1985; 8 (3): 210-214

Abstract

To address the problem of drug dosage as a limiting factor for successful chemotherapy, seven patients with Stage IV neuroblastoma were treated with very high dose cyclophosphamide with imidazole carboximide (DTIC) and vincristine sulfate in conjunction with intensive supportive care. None of the patients experienced a complete response. The major toxicity was myelosuppression, complicated by significant infections. Toxicity was significantly more severe in this study than in similar regimens using these three drugs at conventional doses. Although the number of patients in this study was small and most had received prior therapy, our data do not support the efficacy of very high dose cyclophosphamide in the treatment of Stage IV neuroblastoma.

View details for Web of Science ID A1985ASP2100003

View details for PubMedID 4050739